Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;46(6):2308-2322.
doi: 10.1007/s00261-020-02820-z. Epub 2020 Nov 11.

Radiomics and radiogenomics in ovarian cancer: a literature review

S Nougaret  1   2 , Cathal McCague  3 , Hichem Tibermacine  4   5 , Hebert Alberto Vargas  6 , Stefania Rizzo  7   8 , E Sala  3
Affiliations
Review

Radiomics and radiogenomics in ovarian cancer: a literature review

S Nougaret et al. Abdom Radiol (NY). 2021 Jun.

Abstract

Ovarian cancer remains one of the most lethal gynecological cancers in the world despite extensive progress in the areas of chemotherapy and surgery. Many studies have postulated that this is because of the profound heterogeneity that underpins response to therapy and prognosis. Standard imaging evaluation using CT or MRI does not take into account this tumoral heterogeneity especially in advanced stages with peritoneal carcinomatosis. As such, newly emergent fields in the assessment of tumor heterogeneity have been proposed using radiomics to evaluate the whole tumor burden heterogeneity as opposed to single biopsy sampling. This review provides an overview of radiomics, radiogenomics, and proteomics and examines the use of these newly emergent fields in assessing tumor heterogeneity and its implications in ovarian cancer.

Keywords: Ovarian cancer; Proteomics; Radiogenomics; Radiomics.

PubMed Disclaimer

References

    1. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68 (4):284-296. https://doi.org/10.3322/caac.21456 - PubMed - PMC
    1. Arend R, Martinez A, Szul T, Birrer MJ (2019) Biomarkers in ovarian cancer: To be or not to be. Cancer 125 Suppl 24:4563-4572. https://doi.org/10.1002/cncr.32595 - PubMed
    1. Fujiwara K, Hasegawa K, Nagao S (2019) Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy. Cancer 125 Suppl 24:4582-4586. https://doi.org/10.1002/cncr.32475 - PubMed
    1. Lee JM, Minasian L, Kohn EC (2019) New strategies in ovarian cancer treatment. Cancer 125 Suppl 24:4623-4629. https://doi.org/10.1002/cncr.32544 - PubMed - PMC
    1. Bogani G, Lopez S, Mantiero M, Ducceschi M, Bosio S, Ruisi S, Sarpietro G, Guerrisi R, Brusadelli C, Dell'Acqua A, Di Donato V, Raspagliesi F (2020) Immunotherapy for platinum-resistant ovarian cancer. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2020.05.681

LinkOut - more resources